Dexanabinol

Unknown Manufacturer

Indications

Investigated for use/treatment in traumatic brain injuries and neurologic disorders.

Technical identifiers

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Dexanabinol or a Derivative Thereof for Use in the Treatment of Cancer in Dose Ranges of 2-30 mg/kg
US 2015072020 A1Applicant: E THERAPEUTICS PLCPriority: 2012
CN
EP
US
3 publications
Cancer Cell Apoptosis
US 2012190735 A1Applicant: YOUNG MALCOLM PHILIPPriority: 2009
CN
US
3 publications
Treatment of Melanoma
- US 2011033376 A1
  Applicant: YOUNG MALCOLM PHILIPPriority: 2008
  CN
  US
  2 publications
- US 2011020217 A1
  Applicant: E THERAPEUTICS PLCPriority: 2007
  US
High enantiomeric purity dexanabinol for pharmaceutical compositions
- US 2004110827 A1
  Applicant: AVIV HAIMPriority: 2002
  US
- US 2007060636 A1
  Applicant: AVIV HAIMPriority: 2006
  US
Dexanabinol and dexanabinol analogs regulate inflammation related genes
US 2005137251 A1Applicant: GARZON AARONPriority: 2004
US